Analyzing temozolomide medication errors: potentially fatal.

Area of Science:

• Oncology
• Pharmacology
• Patient Safety

Background:

• Glioblastoma treatment often involves temozolomide (TMZ), an alkylating agent.
• TMZ dosing varies between radiation and maintenance therapy, increasing complexity.
• Multiple capsule strengths of TMZ exist, further complicating accurate dosing.

Purpose of the Study:

• To investigate medication errors associated with temozolomide (TMZ) dosing.
• To identify the types and sources of TMZ medication errors.
• To assess the outcomes of TMZ dosing errors in glioblastoma patients.

Main Methods:

• Reviewed Institute for Safe Medication Practices (ISMP) and FDA MedWatch databases for TMZ-related adverse events.
• Analyzed medication error reports submitted between November 1997 and May 2012.
• Categorized errors by source (patient, dispensing, prescribing) and reported outcomes.

Main Results:

• Identified 45 medication errors, with patient errors (47%) and dispensing errors (29%) being most common.
• Prescribing errors accounted for 16% of reported incidents.
• Outcomes included hematological adverse events (13%), hospitalizations (13%), and fatalities (18%).

Conclusions:

• Despite warnings, temozolomide (TMZ) dosing errors persist due to various factors.
• Errors involve both healthcare professionals and patients, with potentially fatal consequences.
• Enhanced safety protocols are crucial to prevent severe outcomes from TMZ overdosing.